ReviewGenome medicine2017
Narrowing the spectrum: the new frontier of precision antimicrobials.
Review in Genome medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Rapid and modular workflows for same-day sequencing-based detection of bloodstream infections and antimicrobial resistance determinants using culture-enriched samples.Microbiology spectrum · 2026Article
- From Genome Inspection to Precision Agrochemicals: A Structure-Based Antivirulence Roadmap for Sustainable Crop Protection againstJournal of agricultural and food chemistry · 2026Review
- Antimicrobial-resistant Escherichia Coli and Salmonella in poultry production and spread and effect in the one health framework.Poultry science · 2026Review
- Precision antimicrobials: the next paradigm shift after broad-spectrum therapy.Frontiers in microbiology · 2026Article
- MultiSeq-AMR: a modular amplicon-sequencing workflow for rapid detection of bloodstream infection and antimicrobial resistance markers.Microbial genomics · 2025Article
- A novel framework for the automated characterization of Gram-stained blood culture slides using a large-scale vision transformer.Journal of clinical microbiology · 2025Article
- Novel Drug-like HsrA Inhibitors Exhibit Potent Narrow-Spectrum Antimicrobial Activities againstInternational journal of molecular sciences · 2024Article
- Modelling the implementation of narrow versus broader spectrum antibiotics in the empiric treatment of E. coli bacteraemia.Scientific reports · 2024Article
- Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity.Molecules (Basel, Switzerland) · 2024Article
- Early Antibiotic Exposure and Bronchopulmonary Dysplasia in Very Preterm Infants at Low Risk of Early-Onset Sepsis.JAMA network open · 2024Article
- "Antibiotics (Basel, Switzerland) · 2024Article
- L-Thyroxine and L-thyroxine-based antimicrobials against Streptococcus pneumoniae and other Gram-positive bacteria.Heliyon · 2024Article
- Juglone as a Natural Quorum Sensing Inhibitor againstACS pharmacology & translational science · 2024Article
- A low-volume LC/MS method for highly sensitive monitoring of phenoxymethylpenicillin, benzylpenicillin, and probenecid in human serum.Analytical methods : advancing methods and applications · 2024Article
- Effect of antibiotics on physical and physiological development of children under 5-A scoping review.Journal of education and health promotion · 2024Article
- Sequence specificity defines the effectiveness of PPMOs targetingAntimicrobial agents and chemotherapy · 2023Article
- Bloodstream Infections: Comparison of Diagnostic Methods and Therapeutic Consequences between a Hospital in a Resource-Limited Setting and Two French Hospitals.Microorganisms · 2023Article
- Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin.The Journal of antimicrobial chemotherapy · 2023Article
- Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Pathogen-associated gene discovery workflows for novel antivirulence therapeutic development.EBioMedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antibiotics have become the standard of care for bacterial infections. However, rising rates of antibiotic-resistant infections are outpacing the development of new antimicrobials. Broad-spectrum antibiotics also harm beneficial microbial communities inhabiting humans. To combat antibiotic resistance and protect these communities, new precision antimicrobials must be engineered to target specific pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.